联合外周血循环肿瘤细胞评估索拉非尼治疗肝细胞癌疗效？  

Efficacy evaluation of sorafenib in the treatment of hepatocellular carcinoma combined with peripheral circulating tumor cells:Two cases report

作　　者：龙建云[1] 訾晓渊[2] 李静[1] 黄亮[1] 曹杰[1] 严以群[1] 

机构地区：[1]第二军医大学附属东方肝胆外科医院肝外一科,上海200438 [2]第二军医大学干细胞与医学研究中心,200438

出　　处：《临床肿瘤学杂志》2016年第3期275-277,共3页Chinese Clinical Oncology

基　　金：国家自然科学基金(81441063);第二军医大学干细胞与医学研究中心研究生创新实验课题(SCMRC1406)

摘　　要：目的通过联合外周血循环肿瘤细胞(CTC)评估索拉非尼治疗肝细胞癌的疗效,提高对肝癌CTC临床应用的认识。方法本科室基于BIOMARKERBOX平台,利用独特差减富集技术—肿瘤标示物免疫荧光染色—肿瘤细胞染色体荧光原位杂交整合技术平台(SET-i FISH)分离2例肝癌患者外周血,后将肿瘤标示物免疫荧光染色与染色体荧光原位杂交整合为同步进行的检测技术鉴别出CTC,并结合2例患者的临床表现及生存情况进行分析。结果肝癌CTC经SET-i FISH标记为CK-/DAPI+/FISH(CEP8单体)+/CD45-。本科室采用连续3天分离患者外周血(7.5 ml),病例1外周血中检测到CTC 2个,病例2外周血中未见CTC,病例2目前已无瘤生存13个月。结论联合外周血CTC评估索拉非尼治疗肝细胞癌的疗效可能成为一种有效、无创的液体评估手段,为肝癌临床诊治提供新的思路。Objective To evaluate the efficacy of sorafenib in the treatment of hepatocellular carcinoma（ HCC） through com-bined with peripheral circulating tumor cell（ CTC） and to improve the recognition of CTC in HCC. Methods CTCs of two HCC pa-tients were isolated by SET-iFISH technique and were identified by i-FISH. Then we analyzed the patients？ clinical manifestation and long-term survival with CTC. Results CTCs of HCC were marked as CK-/DAPI＋/FISH（CEP8 single）＋/CD45-. We separated 2 patients？ peripheral blood （7？5 ml） in three consecutive days. Patient 1 had 2 CTCs, however, we had not found CTC in patient 2？ s blood. Till now, patient 2 have disease-free survival of 13 months. Conclusion Combination with CTCs can be an effective and nonin-vasive method to analyze the efficacy of sorafenib in the treatment of HCC. It can provide a new prospect in the diagnosis and treatment of HCC.

关 键 词：肝细胞癌 循环肿瘤细胞 索拉非尼 

分 类 号：R735.7[医药卫生—肿瘤]